TY - JOUR
T1 - Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL
AU - Li, Linyu
AU - Zhang, Xuhan
AU - Zhang, Tingting
AU - Song, Zheng
AU - Hu, Ge
AU - Li, Wei
AU - Li, Lanfang
AU - Qiu, Lihua
AU - Qian, Zhengzi
AU - Zhou, Shiyong
AU - Liu, Xianming
AU - Feng, Lixia
AU - Pan, Yi
AU - Zhai, Qiongli
AU - Meng, Bin
AU - Ren, Xiubao
AU - Fu, Kai
AU - Wang, Ping
AU - Wang, Xianhuo
AU - Zhang, Huilai
N1 - Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/10
Y1 - 2018/10
N2 - We investigated the significance of BCL-2 and BCL-6 expression in MYC+ diffuse large B-cell lymphoma. Immunohistochemistry was performed to evaluate the expression of BCL-2, BCL-6, and MYC. BCL-2 played a more important role than MYC in patients with double-expression lymphoma. Besides, BCL-6− expression might also be a negative prognostic factor for such patients. Background: Double-expression lymphoma (DEL) is a rare subgroup of diffuse large B-cell lymphoma (DLBCL), which has coexpression of MYC and BCL-2. Coexpression of MYC and BCL-2 is considered a prognostic marker portending poor outcomes. However, the prognostic effect of BCL-2 and BCL-6 expression in DLBCL remains controversial. Materials and Methods: Immunohistochemical staining was performed to detect MYC, BCL-2 and BCL-6 expression in 212 patients with newly diagnosed DLBCL and assess the prognostic effects of BCL-2 and BCL-6 expression. The DLBCL patients were treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine [Oncovin], prednisone)–like regimens. Results: Retrospective analysis revealed that BCL-2+ and BCL-2+/MYC+ were prognostic factors indicative of poor outcomes. Patients with BCL-2+ and/or MYC+ expression had a poorer prognosis than that of patients with BCL-2− and/or MYC− expression. Patients with BCL-2+/MYC− expression showed a trend toward poorer survival than those with BCL-2−/MYC+ expression, suggesting that BCL-2 plays a more important role than MYC. Also, patients with BCL-6−/MYC+ expression had poorer progression-free survival than those with BCL-6+/MYC+ expression. In addition, patients with BCL-2+/MYC+/BCL-6− expression had the worst prognosis, suggesting that BCL-6− is a prognostic factor for poor outcomes for MYC+ DLBCL patients. Altogether, our findings have shown that BCL-2 is an independent prognostic factor and possibly plays a more important role than MYC in MYC+ DLBCL patients. Furthermore, we found that BCL-6− expression could also be a prognostic factor portending poor outcomes for MYC+ DLBCL patients.
AB - We investigated the significance of BCL-2 and BCL-6 expression in MYC+ diffuse large B-cell lymphoma. Immunohistochemistry was performed to evaluate the expression of BCL-2, BCL-6, and MYC. BCL-2 played a more important role than MYC in patients with double-expression lymphoma. Besides, BCL-6− expression might also be a negative prognostic factor for such patients. Background: Double-expression lymphoma (DEL) is a rare subgroup of diffuse large B-cell lymphoma (DLBCL), which has coexpression of MYC and BCL-2. Coexpression of MYC and BCL-2 is considered a prognostic marker portending poor outcomes. However, the prognostic effect of BCL-2 and BCL-6 expression in DLBCL remains controversial. Materials and Methods: Immunohistochemical staining was performed to detect MYC, BCL-2 and BCL-6 expression in 212 patients with newly diagnosed DLBCL and assess the prognostic effects of BCL-2 and BCL-6 expression. The DLBCL patients were treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine [Oncovin], prednisone)–like regimens. Results: Retrospective analysis revealed that BCL-2+ and BCL-2+/MYC+ were prognostic factors indicative of poor outcomes. Patients with BCL-2+ and/or MYC+ expression had a poorer prognosis than that of patients with BCL-2− and/or MYC− expression. Patients with BCL-2+/MYC− expression showed a trend toward poorer survival than those with BCL-2−/MYC+ expression, suggesting that BCL-2 plays a more important role than MYC. Also, patients with BCL-6−/MYC+ expression had poorer progression-free survival than those with BCL-6+/MYC+ expression. In addition, patients with BCL-2+/MYC+/BCL-6− expression had the worst prognosis, suggesting that BCL-6− is a prognostic factor for poor outcomes for MYC+ DLBCL patients. Altogether, our findings have shown that BCL-2 is an independent prognostic factor and possibly plays a more important role than MYC in MYC+ DLBCL patients. Furthermore, we found that BCL-6− expression could also be a prognostic factor portending poor outcomes for MYC+ DLBCL patients.
KW - Clinic
KW - Diffuse large B-cell lymphoma
KW - Double-expression lymphoma
KW - Prognosis
KW - Retrospective study
UR - http://www.scopus.com/inward/record.url?scp=85049357373&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049357373&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2018.06.010
DO - 10.1016/j.clml.2018.06.010
M3 - Article
C2 - 29983382
AN - SCOPUS:85049357373
SN - 2152-2650
VL - 18
SP - e381-e389
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 10
ER -